Alzheimer’s blood test pTau217 approved for clinical trials in Australia
Consensus Summary
Australia has approved a groundbreaking blood test called pTau217 for clinical trials, which can detect Alzheimer’s disease biomarkers in just 18 minutes. The test, developed by NeuRA and Roche, identifies phosphorylated tau 217, a key indicator of amyloid plaque buildup in the brain, with a diagnostic accuracy of about 90 percent. Both ABC and SMH report that the Asia-Pacific Centre of Excellence for Alzheimer’s Disease Diagnosis in Sydney will enable earlier and more accurate detection, with doctors expected to begin referring patients in the next six to nine months. The test could transform Alzheimer’s care by allowing earlier diagnosis, potentially decades before symptoms appear, and enabling access to disease-modifying therapies sooner. ABC highlights the severe impact of Alzheimer’s, including 17,500 deaths in 2024 and annual costs exceeding $4.7 billion, while SMH emphasizes the test’s role in prevention and early intervention, noting that changes in brain proteins occur 20 to 30 years before symptoms develop.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- The pTau217 blood test can detect Alzheimer’s biomarkers in 18 minutes
- The rollout for doctors to refer patients for the pTau217 test is expected in the next six to nine months
- The Asia-Pacific Centre of Excellence for Alzheimer’s Disease Diagnosis was opened in Sydney
- The Therapeutic Goods Administration (TGA) approved the pTau217 test for clinical use
- Alzheimer’s disease is the most common form of dementia in Australia
- The pTau217 test detects phosphorylated tau 217, a biomarker for amyloid plaque buildup in the brain
- The test has a diagnostic accuracy of about 90 percent
Points of Difference
Details reported by only one source:
- Dementia, including Alzheimer’s disease, accounted for over 17,500 deaths in 2024, making it the nation’s leading cause of death
- Annual costs of dementia already surpass $4.7 billion
- Chris Raper, a union official at the Miscellaneous Workers Union, died on Monday after being severely affected by dementia
- The test could detect changes in the brain 20 years earlier than symptom onset (implied by 'decades earlier')
- The announcement was made at the launch of the Asia-Pacific Centre of Excellence for Alzheimer’s Disease Diagnosis in Sydney, a collaboration between NeuRA and Roche
- Changes in amyloid and tau proteins occur 20 to 30 years before people develop Alzheimer’s symptoms
- The TGA approved another blood test called pTau181 in October, used as a 'rule-out' test for mild cognitive impairment
- The pTau217 test is a 'rule-out' and 'rule-in' test, identifying people with or without Alzheimer’s pathology, with a 'grey zone' requiring confirmatory tests
- The centre will process blood tests and cerebrospinal fluid samples for clinical trials, with national guidelines expected to be developed over several years
- The pTau217 test may eventually be used for screening early stages of Alzheimer’s even before symptoms appear
Contradictions
Conflicting information between sources:
- ABC states the test can detect changes 'decades earlier' (implied by '20 years earlier'), while SMH specifies '20 to 30 years before people develop symptoms'
- ABC mentions the test is expected to be rolled out in 'the next six to nine months' without additional timeframes, while SMH adds that clinicians will need 'developmental training' over 'several years' before widespread use
Source Articles
Test that could identify Alzheimer's signs 20 years earlier greenlit for trials
The ability to diagnose Alzheimer's decades earlier could be a step closer with a new blood test set for clinical trials within months.
Alzheimer’s blood test to give Australians invaluable gift of time
Australians will soon have access to the first diagnostic blood test for Alzheimer’s disease that researchers say will transform early detection, treatment and potentially prevention.